Amelioration of lupus nephritis by serum amyloid P component gene therapy with distinct mechanisms varied from different stage of the disease.
about
Host responses in tissue repair and fibrosisPentraxins: structure, function, and role in inflammationInhibition of aberrant circulating Tfh cell proportions by corticosteroids in patients with systemic lupus erythematosus.Interleukin-17 expression positively correlates with disease severity of lupus nephritis by increasing anti-double-stranded DNA antibody production in a lupus model induced by activated lymphocyte derived DNA.Mannose-binding lectin blunts macrophage polarization and ameliorates lupus nephritis.Granulin exacerbates lupus nephritis via enhancing macrophage M2b polarization.Pentraxins and Fc receptorsDNA-dependent activator of interferon-regulatory factors (DAI) promotes lupus nephritis by activating the calcium pathway.Breaking immunological tolerance in systemic lupus erythematosus.Cell-free and cell-bound circulating nucleic acid complexes: mechanisms of generation, concentration and content.New approaches to modulating idiopathic pulmonary fibrosis.New approaches for the treatment of lupus nephritis in the 21st century: from the laboratory to the clinic.Incomplete clearance of apoptotic cells in systemic lupus erythematosus: pathogenic role and potential biomarker.Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis.Hyperactivation of the NLRP3 Inflammasome in Myeloid Cells Leads to Severe Organ Damage in Experimental Lupus.Immunosuppressive Effect of B7-H4 Pathway in a Murine Systemic Lupus Erythematosus Model.Interleukin-6 promotes systemic lupus erythematosus progression with Treg suppression approach in a murine systemic lupus erythematosus model.Kinetics of circulating cell-free DNA for biomedical applications: critical appraisal of the literature.
P2860
Q26852800-6B9C134C-FE47-43A0-B363-0833FFF8A93BQ28676262-7E911A5F-87B3-4DD1-838B-0C45303DFB57Q34532672-7F59C9E1-E6B4-4446-A20F-49451A41AE04Q34614743-AC61B9AD-4CC3-4549-91C8-C6FA19BDF612Q34693167-7B833E5E-C977-49F1-9F86-CEE72358679EQ34766619-4D3B03E9-E739-4BEC-BAED-29CAA60C7B0AQ36317664-6BA07C50-F36D-49ED-B19A-3005EAF5D29AQ36832638-86CE9CDE-3725-421F-8B34-71B92A4D5BF6Q37705429-A10FBBF5-BB90-41B9-984F-71792DCD212AQ38002456-4AFAFB5A-32A0-4067-8117-72957C965800Q38130161-5F3B96ED-96D4-4127-AB0E-F32CCCF595D5Q38148585-06F7F595-3EBB-475B-AFDB-5AFD046EAB18Q38425946-1375541C-44C0-46BA-960A-A325EC4AA6CEQ38926368-BEF1F933-5EA9-41DB-879D-FDE952D10CD4Q40401297-C4FB96C7-1C7D-4E4F-ADE7-D8E93CF4C31EQ47389712-6D4ABE1F-0A8F-45DE-86E9-32DC9560CAABQ51134392-8FBB2093-22A1-477A-8392-BF181DAA8806Q52571170-1409354A-EB92-4F46-AF1C-96CD77FD0743
P2860
Amelioration of lupus nephritis by serum amyloid P component gene therapy with distinct mechanisms varied from different stage of the disease.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Amelioration of lupus nephriti ...... ifferent stage of the disease.
@ast
Amelioration of lupus nephriti ...... ifferent stage of the disease.
@en
type
label
Amelioration of lupus nephriti ...... ifferent stage of the disease.
@ast
Amelioration of lupus nephriti ...... ifferent stage of the disease.
@en
prefLabel
Amelioration of lupus nephriti ...... ifferent stage of the disease.
@ast
Amelioration of lupus nephriti ...... ifferent stage of the disease.
@en
P2093
P2860
P1433
P1476
Amelioration of lupus nephriti ...... ifferent stage of the disease.
@en
P2093
P2860
P304
P356
10.1371/JOURNAL.PONE.0022659
P407
P577
2011-07-25T00:00:00Z